| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
From the Clinical Research Centers |
2 Pro12Ala Variant on Obesity, Glucose Homeostasis, and Blood Pressure in Members of Familial Type 2 Diabetic Kindreds1
Department of Human Genetics, University of Utah (S.J.H.), Salt Lake City, Utah 84112-5330; and Division of Endocrinology, Department of Medicine, Central Arkansas Veterans Healthcare System and University of Arkansas for Medical Sciences (Q.-F.R., K.T., S.C.E.), Little Rock, Arkansas 72205
Address all correspondence and requests for reprints to: Steven C. Elbein, M.D., Endocrinology 111J/LR, 4300 West 7th Street, Little Rock, Arkansas 72205. E-mail: elbeinstevenc{at}exchange.uams.edu
The Pro12Ala (P12A) variant of exon B of the peroxisome
proliferator-activated receptor
2 (PPAR
) been
variably associated with obesity, insulin sensitivity, diabetes, and
dyslipidemia, but its role in insulin resistance-associated traits
remains uncertain. We tested the hypothesis that this variant is
associated with the insulin resistance syndrome by genotyping 619
members of 52 familial type 2 diabetes kindreds. A subset of 124 family
members underwent iv glucose tolerance tests and minimal model
determination of insulin sensitivity. We estimated the frequency of the
A12 allele as 0.12, within the range observed in random Caucasian
samples. We were unable to demonstrate any effect on direct measures of
insulin sensitivity, and no trait was linked to markers near PPAR
on
chromosome 3q. However, body mass index, serum total cholesterol
levels, triglyceride levels, systolic and diastolic blood pressures,
and glucose concentration showed at least a trend to association
(P < 0.1) when tested separately for a
family-based association. When these 6 traits were included in a
multivariate analysis, body mass index, systolic and diastolic blood
pressures, triglyceride levels, and glucose concentration remained
significantly associated with the P12A variant (P
< 0.05), whereas the effect of P12A on liability for diabetes was not
significant. The predicted means for each trait and each genotype
suggested that the P12A variant acted most like a recessive mutation,
with the major effect among homozygous individuals who comprise only
12% of the population. We confirm an association of the P12A variant
in traits commonly ascribed to the insulin resistance syndrome, but not
with direct measures of insulin sensitivity. The tendency for this
variant to act in a recessive manner with effects on multiple traits
may explain the inconsistent associations noted in previous studies.
This article has been cited by other articles:
![]() |
ABDOMINAL OBESITY STUDY GROUP, F. E. VON EYBEN, J. P. KROUSTRUP, J. F. LARSEN, and J. CELIS Comparison of Gene Expression in Intra-Abdominal and Subcutaneous Fat: A Study of Men with Morbid Obesity and Nonobese Men Using Microarray and Proteomics Ann. N.Y. Acad. Sci., December 1, 2004; 1030(1): 508 - 536. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Orio Jr., S. Palomba, T. Cascella, S. Di Biase, D. Labella, T. Russo, S. Savastano, F. Zullo, A. Colao, R. Vettor, et al. Lack of an Association between Peroxisome Proliferator-Activated Receptor-{gamma} Gene Pro12Ala Polymorphism and Adiponectin Levels in the Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., October 1, 2004; 89(10): 5110 - 5115. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Temelkova-Kurktschiev, M. Hanefeld, G. Chinetti, C. Zawadzki, S. Haulon, A. Kubaszek, C. Koehler, W. Leonhardt, B. Staels, and M. Laakso Ala12Ala Genotype of the Peroxisome Proliferator-Activated Receptor {gamma}2 Protects against Atherosclerosis J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4238 - 4242. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. Colca, W. G. McDonald, D. J. Waldon, J. W. Leone, J. M. Lull, C. A. Bannow, E. T. Lund, and W. R. Mathews Identification of a novel mitochondrial protein ("mitoNEET") cross-linked specifically by a thiazolidinedione photoprobe Am J Physiol Endocrinol Metab, February 1, 2004; 286(2): E252 - E260. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Orio Jr., G. Matarese, S. Di Biase, S. Palomba, D. Labella, V. Sanna, S. Savastano, F. Zullo, A. Colao, and G. Lombardi Exon 6 and 2 Peroxisome Proliferator-Activated Receptor-{gamma} Polymorphisms in Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., December 1, 2003; 88(12): 5887 - 5892. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Poulsen, G. Andersen, M. Fenger, T. Hansen, S. M. Echwald, A. Volund, H. Beck-Nielsen, O. Pedersen, and A. Vaag Impact of Two Common Polymorphisms in the PPAR{gamma} Gene on Glucose Tolerance and Plasma Insulin Profiles in Monozygotic and Dizygotic Twins: Thrifty Genotype, Thrifty Phenotype, or Both? Diabetes, January 1, 2003; 52(1): 194 - 198. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. I. Lindi, M. I.J. Uusitupa, J. Lindstrom, A. Louheranta, J. G. Eriksson, T. T. Valle, H. Hamalainen, P. Ilanne-Parikka, S. Keinanen-Kiukaanniemi, M. Laakso, et al. Association of the Pro12Ala Polymorphism in the PPAR-{gamma}2 Gene With 3-Year Incidence of Type 2 Diabetes and Body Weight Change in the Finnish Diabetes Prevention Study Diabetes, August 1, 2002; 51(8): 2581 - 2586. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. C. Elbein Perspective: The Search for Genes for Type 2 Diabetes in the Post-Genome Era Endocrinology, June 1, 2002; 143(6): 2012 - 2018. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |